15-17毫米机械二尖瓣置换的多中心结局研究
该多中心回顾性队列研究纳入6个先天性心脏病中心的61例婴儿,评估15-17毫米机械二尖瓣置换的早期和中期结局。院内死亡13例(21%),晚期死亡8例(17%),首次瓣膜再置换27例(44%),中位再置换时间3.7年,无瓣膜置换相关死亡。结论认为该小尺寸机械瓣是危重婴幼儿二尖瓣无法修复时的重要选择,因生长发育导致的再置换风险较低。
要点
- 61例婴儿中院内死亡21%,晚期死亡17%,主要不良事件56%。
- 44%患儿需首次瓣膜再置换,中位时间3.7年,无置换相关死亡。
- 该小尺寸机械瓣是危重婴幼儿二尖瓣无法修复时的重要替代方案。
核心结论
- 15-17毫米机械二尖瓣置换是危重新生儿和婴儿二尖瓣无法修复时的重要替代方案。
- 因生长发育导致的瓣膜再置换风险较低,无瓣膜置换相关死亡。
研究设计与样本
- 多中心回顾性队列研究,纳入6个先天性心脏病中心(荷兰5个、美国1个)。
- 共61例婴儿接受15-17毫米机械二尖瓣置换,15毫米17例(28%)、16毫米18例(29%)、17毫米26例(43%)。
主要发现
- 院内死亡13例(21%),晚期死亡8例(17%, among 48 hospital survivors)。
- 主要不良事件34例(56%),中位随访4.0年(IQR 0.4-12.5)。
- 首次瓣膜再置换27例(44%),中位时间3.7年(IQR 1.9-6.8)。
- 未报告人工瓣膜心内膜炎,无瓣膜置换相关死亡。
- 其他再干预包括永久起搏器植入9例(15%)、主动脉瓣下狭窄切除4例(7%)、主动脉瓣修复3例(5%)、主动脉瓣置换6例(10%)。
临床怎么用
- 对于危重婴儿二尖瓣无法修复者,可考虑使用15-17毫米机械瓣作为挽救性方案。
- 术后需密切监测瓣膜功能及生长发育,再置换手术风险较低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this study was to evaluate early and mid-term outcomes (mortality and prosthetic valve reintervention) after mitral valve replacement with 15- to 17-mm mechanical prostheses. METHODS: A multicenter, retrospective cohort study was performed among patients who underwent mitral valve replacement with a 15- to 17-mm mechanical prosthesis at 6 congenital cardiac centers: 5 in The Netherlands and 1 in the United States. Baseline, operative, and follow-up data were evaluated. RESULTS: Mitral valve replacement was performed in 61 infants (15 mm, n = 17 [28%]; 16 mm, n = 18 [29%]; 17 mm, n = 26 [43%]), of whom 27 (47%) were admitted to the intensive care unit before surgery and 22 (39%) required ventilator support. Median age at surgery was 5.9 months (interquartile range [IQR] 3.2-17.4), and median weight was 5.7 kg (IQR, 4.5-8.8). There were 13 in-hospital deaths (21%) and 8 late deaths (17%, among 48 hospital survivors). Major adverse events occurred in 34 (56%). Median follow-up was 4.0 years (IQR, 0.4-12.5) First prosthetic valve replacement (n = 27 [44%]) occurred at a median of 3.7 years (IQR, 1.9-6.8). Prosthetic valve endocarditis was not reported, and there was no mortality related to prosthesis replacement. Other reinterventions included permanent pacemaker implantation (n = 9 [15%]), subaortic stenosis resection (n = 4 [7%]), aortic valve repair (n = 3 [5%], and aortic valve replacement (n = 6 [10%]). CONCLUSIONS: Mitral valve replacement with 15- to 17-mm mechanical prostheses is an important alternative to save critically ill neonates and infants in whom the mitral valve cannot be repaired. Prosthesis replacement for outgrowth can be carried out with low risk.
引用
- IJsselhof RJ, Slieker MG, Gauvreau K, et al. Mechanical Mitral Valve Replacement: A Multicenter Study of Outcomes With Use of 15- to 17-mm Prostheses. Ann Thorac Surg. 2020. PMID: 32525029. doi:10.1016/j.athoracsur.2020.04.084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。